BioSpace News Archive

BioMidwest

Sales of Disposable Diabetes Testing Supplies to Exceed 5% Annual Growth

Demand for disposable diabetes testing supplies is expected to increase 5.1% annually to more than $3.9 billion in 2022.

July 25, 2018
·
2 min read
Drug Development

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study evaluating the efficacy and safety of its investigational Port Delivery System with ranibizumab (PDS)...

July 25, 2018
·
9 min read
Business

Mauna Kea Technologies Reports Second Quarter and First Half 2018 Sales

U.S. momentum underway with 12 new Cellvizio® deals in Q2, including 11 consignments vs. 2 in Q2 2017

July 25, 2018
·
8 min read
Diabetic Neuropathy | A Pipeline Analysis Report 2018 | Technavio

Technavio has announced their latest pipeline analysis report on the diabetic neuropathy market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat diabetic neuropathy.

July 25, 2018
·
4 min read
Pertussis | A Drug Pipeline Analysis Report 2018 | Technavio

Technavio has announced their latest pipeline analysis report on the pertussis market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat pertussis.

July 25, 2018
·
4 min read
Business

MEDISCA Announces Exclusive Partnership with German Manufacturer SAMIX

MEDISCA will be the North American Distributor of Highly Reliable New SAMIX® Product Line

July 25, 2018
·
3 min read
Polymyositis | A Pipeline Molecule Analysis Report 2018 | Technavio

Technavio has announced their latest pipeline analysis report on the polymyositis market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat polymyositis.

July 25, 2018
·
3 min read
Biotech Bay

McKesson Announces Preliminary Voting Results from 2018 Annual Meeting of Stockholders

All Directors Re-elected, Advisory Vote on Executive Compensation Approved, All Board Vote Recommendations Supported

July 25, 2018
·
1 min read
Drug Development

KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20)

KEYTRUDA is the First Anti-PD-1 Therapy to Show an Overall Survival Benefit as First-Line Therapy for Recurrent or Metastatic HNSCC

July 25, 2018
·
29 min read
Business

Indivior Announces H1 2018 Results

Indivior Announces H1 2018 Results

July 25, 2018
·
100 min read